Costs and Consequences of Using Interferon-γ Release Assays for the Diagnosis of Active Tuberculosis

Published Date:

04/28/2015

Source:

PubMed - NCBI

Authors:

Little KM, Pai M, Dowdy DW

External link

Original Article

There is growing concern that interferon-γ release assays (IGRAs) are being used off-label for the diagnosis of active tuberculosis (TB) disease in many high-burden settings, including India, where the background prevalence of latent TB infection is high. We analyzed the costs and consequences of using IGRAs for the diagnosis of active TB in India from the perspective of the Indian TB control sector.

Events

«

June 2017

»
S
M
T
W
T
F
S
·
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
·

Projects

ACTG trial A5343

Phase 2 safety study of bedaquiline and delamanid for the treatment of MDR-TB in South Africa

Read More

Understanding the role of repeat testing and...

We have developed a Markov model of serial IGRA testing to help improve testing algorithms with TST vs. IGRA in low-risk...

Read More

Quantitative assessment of the tipping point...

Quantitative methods will be used to study Mtb dynamics to determine the tipping point for macrophage infection, which depends...

Read More

Comparative implementation and...

We are conducting a randomized comparative implementation trial across 56 sites in rural South Africa to evaluate three...

Read More